Literature DB >> 27903853

Intraperitoneal Calcitriol for Treatment of Severe Hyperparathyroidism in Children with Chronic Kidney Disease: A Therapy Forgotten.

Rahul Chanchlani1,2,3, Susan Ackerman1, Elizabeth Piva1, Elizabeth Harvey4.   

Abstract

Active Vitamin D sterols such as calcitriol and alfacalcidol are quite effective in the treatment of mineral bone disease secondary to chronic kidney disease. However, some children on peritoneal dialysis (PD) are resistant to oral formulations of active Vitamin D, and use of an intravenous formulation in such patients is inconvenient. In these children, intraperitoneal (IP) calcitriol has been shown to be effective in the treatment of secondary hyperparathyroidism. However, its use has declined. We report 2 children, aged 1 and 9.5 years, on chronic cycler PD with severe secondary hyperparathyroidism refractory to oral active Vitamin D who were successfully treated with IP calcitriol for a period of 12 and 4 months, respectively. We also discuss the published literature on the efficacy of IP calcitriol for treatment of secondary hyperparathyroidism and specific considerations for its use in PD patients.
Copyright © 2016 International Society for Peritoneal Dialysis.

Entities:  

Keywords:  Secondary hyperparathyroidism; calcitriol; chronic kidney disease; peritoneal dialysis

Mesh:

Substances:

Year:  2016        PMID: 27903853      PMCID: PMC5174879          DOI: 10.3747/pdi.2015.00215

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  11 in total

Review 1.  Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy.

Authors:  J W Coburn
Journal:  Kidney Int Suppl       Date:  1990-09       Impact factor: 10.545

2.  Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients.

Authors:  I B Salusky; W G Goodman; R Horst; G V Segre; L Kim; K C Norris; J S Adams; M Holloway; R N Fine; J W Coburn
Journal:  Am J Kidney Dis       Date:  1990-08       Impact factor: 8.860

3.  Intraperitoneal pulse calcitriol in the treatment of secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.

Authors:  H W Chan; W K Tsang; C M Chan; S K Fung; S O So; H L Tang; M K Tong; K C Lee; A Y Chan
Journal:  Perit Dial Int       Date:  1998 Mar-Apr       Impact factor: 1.756

4.  Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.

Authors:  I B Salusky; B D Kuizon; T R Belin; J A Ramirez; B Gales; G V Segre; W G Goodman
Journal:  Kidney Int       Date:  1998-09       Impact factor: 10.612

5.  The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.

Authors:  M Wada; Y Furuya; J Sakiyama; N Kobayashi; S Miyata; H Ishii; N Nagano
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

6.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Authors:  Ming Teng; Myles Wolf; Edmund Lowrie; Norma Ofsthun; J Michael Lazarus; Ravi Thadhani
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

7.  Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism.

Authors:  Justine Bacchetta; Ingrid Plotton; Bruno Ranchin; Thierry Vial; Marc Nicolino; Yves Morel; Pierre Cochat
Journal:  Nephrol Dial Transplant       Date:  2009-05-06       Impact factor: 5.992

8.  The effects of intraperitoneal calcitriol on calcium and parathyroid hormone.

Authors:  J A Delmez; C S Dougan; B K Gearing; M Rothstein; D W Windus; N Rapp; E Slatopolsky
Journal:  Kidney Int       Date:  1987-03       Impact factor: 10.612

9.  Losses of calcitriol to peritoneal dialysis bags and tubing.

Authors:  R Vieth; S E Ledermann; S W Kooh; J W Balfe
Journal:  Perit Dial Int       Date:  1989       Impact factor: 1.756

10.  An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.

Authors:  Desmond Padhi; Craig B Langman; Sahar Fathallah-Shaykh; Bradley A Warady; Isidro B Salusky; Edward Lee; Christine Wang; Edward Posvar
Journal:  Pediatr Nephrol       Date:  2012-05-26       Impact factor: 3.714

View more
  1 in total

1.  Efficacy and safety of cinacalcet and active vitamin D in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease: a network meta-analysis.

Authors:  Li-Hua Ni; Cheng Yuan; Kai-Yun Song; Xiao-Chen Wang; Si-Jie Chen; Li-Ting Wang; Yu-Xia Zhang; Hong Liu; Bi-Cheng Liu; Ri-Ning Tang
Journal:  Ann Transl Med       Date:  2019-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.